Use of cangrelor in percutaneous coronary interventions: a “new” weapon in the antithrombotic therapeutic armamentarium
During the second half of 2019, cangrelor started selling in our country, a “new” antiplatelet drug with especial pharmacological properties that make it especially appealing for the management of certain clinical situations in the percutaneous coronary intervention (PCI) setting. The adjective “new...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2020-11-01
|
| Series: | REC: Interventional Cardiology (English Ed.) |
| Online Access: | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=478 |